News

Strongbridge Expecting Second Patent on Cushing’s Treatment Recorlev

Strongbridge Biopharma is expecting a second patent on its Cushing’s syndrome therapy Recorlev (levoketoconazole). The signal it received was the U.S. Patent and Trademark Office completing a review of its new patent application for the cortisol synthesis inhibitor. The second patent, which would expire Jan. 10, 2026, would cover other conditions in…

Study Examines Therapy Options for Post-adrenalectomy Low Glucocorticoid Levels

Hydrocortisone and prednisone have comparable safety and effectiveness when used as glucocorticoid replacement therapy in patients with adrenal adenoma or Cushing’s disease who underwent adrenalectomy, a new study shows. The study, “Comparison of hydrocortisone and prednisone in the glucocorticoid replacement therapy post-adrenalectomy of Cushing’s Syndrome,” was published in the journal…